More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.38B
EPS
-3.87
P/E ratio
--
Price to sales
29.72
Dividend yield
--
Beta
1.065646
Previous close
$30.87
Today's open
$30.69
Day's range
$29.75 - $31.37
52 week range
$13.18 - $34.29
show more
CEO
Stephen Mahoney
Employees
252
Headquarters
Waltham, MA
Exchange
NASDAQ Capital Market
Shares outstanding
113558449
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.
Benzinga • Nov 9, 2026

Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript
Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Dina Elmonshed - UBS Investment Bank, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Qiu Wu - Goldman Sachs Group, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call.
Seeking Alpha • Nov 9, 2026

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every 8 weeks can deliver deep and sustain.
Business Wire • Nov 9, 2026

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and.
Business Wire • Nov 6, 2026

Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 6, 2026

Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead
Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as well-positioned for continued growth, with more growth expected to come from elegrobart in late 2027. VRDN's near-term focus is on phase 1 data for VRDN-008 in the FcRn franchise, with expectations for deep IgG lowering and good safety and tolerability.
Seeking Alpha • Nov 5, 2026

What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30.
MarketBeat • Nov 4, 2026

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026. "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Offi.
Business Wire • Nov 4, 2026

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Viridian Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.